Brown Brothers Harriman & CO T Scan Therapeutics, Inc. Transaction History
Brown Brothers Harriman & CO
- $14 Billion
- Q3 2024
A detailed history of Brown Brothers Harriman & CO transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Brown Brothers Harriman & CO holds 143,051 shares of TCRX stock, worth $360,488. This represents 0.01% of its overall portfolio holdings.
Number of Shares
143,051
Previous 76,024
88.17%
Holding current value
$360,488
Previous $444,000
60.36%
% of portfolio
0.01%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding TCRX
# of Institutions
90Shares Held
42.3MCall Options Held
0Put Options Held
0-
Lynx1 Capital Management LP San Juan, PR5.22MShares$13.2 Million9.31% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5MShares$12.6 Million1.08% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$11.2 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.4MShares$11.1 Million0.04% of portfolio
-
Bvf Inc San Francisco, CA2.99MShares$7.53 Million0.47% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $47.7M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...